Botensilimab + Balstilimab

Phase 2

AGENUS INC (AGEN)

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

12 competitors in Non-small Cell Lung Cancer

REGNLibtayo

Phase 3

MRKArm A: Pemetrexed Cisplatin

Phase 2

SNYoxaliplatine / gemcitabine / Vinorelbine

Drug Information

Target Indication

Non-small Cell Lung Cancer

Clinical Trial

NCT06322108

Last updated: 10/17/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

AGEN

AGENUS INC

Biological Products, (No Diagnostic Substances)•North America•NASDAQ

Related Pipeline

HSPPC-96 or OncophagePhase 3

Malignant Melanoma

BalstilimabPhase 3

Advanced Melanoma

autologous human tumor-derived HSPPC-96Phase 3

Renal Cell Carcinoma

BotensilimabPhase 3

Metastatic Pancreatic Ductal Adenocarcinoma

FLOT (Fluorouracil+Leucovorin+Oxaliplatin+Docetaxel)Phase 3

Resectable MMR-deficient Solid Tumors

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts